Welcome to QuidelOrtho’s Q4 2024 Results Conference Call
Company Participants:
Juliet Cunningham – Vice President, Investor Relations
Brian Blaser – President and Chief Executive Officer
Joe Busky – Chief Financial Officer
During the Q4 2024 Results Conference Call held on February 12, 2025, QuidelOrtho Corporation (NASDAQ:QDEL) discussed the financial performance for the fourth quarter and full year of 2024. The call was led by Brian Blaser, President and CEO, along with other key executives including Vice President Juliet Cunningham and CFO Joe Busky.
Participants on the call included analysts such as Jack Meehan from Nephron Research, Patrick Donnelly from Citi, and Bill Bonello from Craig-Hallum among others. The call provided insights into the financial results and strategic direction of QuidelOrtho.
Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode.
How Will This Affect Me?
As an investor or shareholder in QuidelOrtho Corporation, the Q4 2024 Results Conference Call and the financial performance discussed during the call are crucial information for making informed decisions regarding your investment in the company. Understanding the company’s financial health and strategic direction can help you assess the potential impact on your investment portfolio.
How Will This Affect the World?
QuidelOrtho Corporation is a significant player in the healthcare industry, particularly in the field of diagnostic testing. The company’s performance and strategic decisions can have ripple effects on the healthcare sector and the larger economy. Positive financial results and growth prospects for QuidelOrtho can contribute to advancements in healthcare technology and solutions, ultimately benefiting patients and healthcare providers worldwide.
Conclusion
The Q4 2024 Results Conference Call provided valuable insights into QuidelOrtho Corporation’s financial performance and strategic direction. As investors and industry watchers, understanding the implications of these results is essential for making informed decisions and predicting the impact on the global healthcare landscape.
